BRAF and melanoma: In addition, the expression level of lncRNA-TSLNC8 is downregulated in BRAF inhibitor-resistant melanoma cells, and its low expression attenuates the toxicity response of tumor cells to PLX4720 (a type of BRAF inhibitor).